<DOC>
	<DOCNO>NCT02367924</DOCNO>
	<brief_summary>Efficacy safety trabectedin real-life practice , routinely used management advance sarcoma failure anthracyclines ifosfamide patient unsuited receive drug Germany . Trabectedin indicate treatment patient advance soft tissue sarcoma , failure anthracyclines ifosfamide , unsuited receive agent . Efficacy data base mainly liposarcoma leiomyosarcoma patient .</brief_summary>
	<brief_title>Efficacy Safety Trabectedin ( YondelisÂ® ) Patients With Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description>This non-interventional , observational prospective study evaluate efficacy safety trabectedin routine practice . Patients assign therapeutic strategy within current practice , accord trial protocol . The prescription medicine separate decision include patient study . Diagnostic monitoring procedure ordinarily apply therapeutic strategy . There dose regimen medical procedure define within study plan . Every medical decision course treatment trabectedin reflect exclusively decision Investigator routine clinical situation accord SmPC . The concept non-interventional study documentation procedure affect way routine treatment situation .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Patients must comply follow criterion order enrol study : Histologically diagnose advanced STS Female male age 18 year Signed write informed consent Suitable undergo treatment trabectedin accord SmPC Progress therapy anthracyclines ifosfamide fail , patient unsuited receive agent Patients present contraindication use trabectedin define SmPC exclude participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>